A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the
efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for
SCLC.